Law firms Robbins LLP and Hagens Berman cite alleged misstatements about Embecta’s pen needle business before a May 5, 2026 guidance cut, 93% dividend reduction, and roughly 58% one-day share price drop.
Law firms Robbins LLP and Hagens Berman said investors who purchased Embecta Corp. securities between Nov. 25, 2025 and May 4, 2026 may be part of a proposed securities class action pending in the U.S. District Court for the District of New Jersey, with an Aug. 17, 2026 deadline to seek appointment as lead plaintiff. The complaint alleges Embecta misled investors by reaffirming fiscal 2026 guidance and describing its pen needle business as stable and resilient despite alleged competitive share loss at a major customer and softer retail-channel volumes. On May 5, 2026, Embecta disclosed it had missed second-quarter fiscal 2026 guidance, cut full-year 2026 guidance sharply, and reduced its quarterly dividend from $0.15 to $0.01 per share, after which the stock fell about 57% to 57.8% in a single trading day, closing at $3.90.